Results 211 to 220 of about 24,558,950 (403)
Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancer
We aggregated a cohort of 1012 mCRPC tissue samples from 769 patients and investigated the association of gene expression‐based pathways with clinical outcomes. Loss of AR signaling, high proliferation, and a glycolytic phenotype were independently prognostic for poor outcomes, and an adverse transcriptional feature score incorporating these pathways ...
Marina N. Sharifi+26 more
wiley +1 more source
Phase change material-based thermal energy storage
Tianyu Yang, W. King, N. Miljkovic
semanticscholar +1 more source
TOMM20 increases cancer aggressiveness by maintaining a reduced state with increased NADH and NADPH levels, oxidative phosphorylation (OXPHOS), and apoptosis resistance while reducing reactive oxygen species (ROS) levels. Conversely, CRISPR‐Cas9 knockdown of TOMM20 alters these cancer‐aggressive traits.
Ranakul Islam+9 more
wiley +1 more source
Coherent Structure in Indium Doped Phase Change Materials. [PDF]
Wang R+9 more
europepmc +1 more source
Presurgery 72‐h fasting in GB patients leads to adaptations of plasma lipids and polar metabolites. Fasting reduces lysophosphatidylcholines and increases free fatty acids, shifts triglycerides toward long‐chain TGs and increases branched‐chain amino acids, alpha aminobutyric acid, and uric acid.
Iris Divé+7 more
wiley +1 more source
Viscoelasticity and accretive phase-change at finite strains. [PDF]
Chiesa A, Stefanelli U.
europepmc +1 more source
Patient engagement involves actively including patients in healthcare decisions and research to ensure care and studies align with their needs. This approach improves outcomes, trust, and communication while fostering collaboration between patients and professionals.
Estela Cepeda+3 more
wiley +1 more source
Research on the performance of phase change energy storage devices based on solar energy. [PDF]
Xu N+7 more
europepmc +1 more source
This study investigates an alternative approach to reactivating the oncosuppressor p53 in cancer. A short peptide targeting the association of the two p53 inhibitors, MDM2 and MDM4, induces an otherwise therapeutically active p53 with unique features that promote cell death and potentially reduce toxicity towards proliferating nontumor cells.
Sonia Valentini+10 more
wiley +1 more source